Lexeo Therapeutics agrees to buy Mantle Therapeutics for up to $21.3 million

By Public Technologies
  • Lexeo Therapeutics reached a definitive agreement to acquire Mantle Therapeutics, adding several frataxin-restoration programs targeting Friedreich ataxia neurology.
  • Consideration totals USD 8.3 million upfront in cash and equity, with up to USD 13 million in milestone payments in cash and equity.
  • Deal value could reach USD 21.3 million; closing is expected in the third quarter of 2026, subject to customary conditions.
  • Acquired assets include a clinical-stage oral combination therapy, a preclinical CNS-penetrant small molecule, and TfR1-based brain-delivery biologics.
  • Cash runway guidance remains into 2028; an IND for the next FA development candidate is targeted for 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220700PRIMZONEFULLFEED9831067) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.